At a glance
| Product | Netspot |
|---|---|
| Role | Diagnostic PET tracer |
| Target | Somatostatin receptors, especially SSTR2 |
| Route | Intravenous in nuclear medicine |
| Important distinction | Diagnostic, not therapeutic |
Overview
Netspot is a preparation kit used to produce gallium-68 dotatate for specialist nuclear-medicine imaging. Many well-differentiated neuroendocrine tumors express somatostatin receptors, allowing this tracer to help locate disease and characterize receptor expression. Findings can contribute to staging and treatment planning, including assessment for receptor-targeted radionuclide therapy. The result is interpreted with clinical information and other imaging. A bright focus is not automatically malignant, and a negative scan does not exclude every neuroendocrine tumor, especially when receptor expression is low or heterogeneous.
How it works
Dotatate binds somatostatin receptors, particularly subtype 2. Gallium-68 attached through a chelator emits positrons, which generate the signal detected by PET. Uptake depends on receptor expression and normal tracer handling. Physiologic activity in organs and uptake in nonmalignant conditions can complicate interpretation. Unlike lutetium-177 dotatate, the gallium-labeled preparation is optimized for imaging rather than therapeutic radiation delivery.
Approved imaging role
The U.S. indication is PET localization of somatostatin receptor-positive neuroendocrine tumors in adults and children. The study is organized by a nuclear-medicine service with licensed radiopharmaceutical preparation and radiation-safety procedures.
Supporting sources [1]
Why receptor imaging is useful
A prospective study evaluated detection of gastroenteropancreatic neuroendocrine tumors and unknown primary sites with gallium-68 dotatate. It demonstrated clinically useful lesion detection compared with conventional approaches, but detection performance depends on tumor type and the reference standard used.
Supporting sources [2]
What uptake does and does not mean
Normal tissues, inflammatory processes and some non-neuroendocrine tumors may take up tracer. Tumors with little somatostatin receptor expression can be missed. The scan therefore supports a diagnostic assessment; it does not independently establish histology or replace all other tests.
Supporting sources [1]
Radiation and patient considerations
Exposure adds to cumulative medical radiation. Hypersensitivity reactions are possible. Pregnancy, breastfeeding, renal clearance and other somatostatin-directed medicines require attention to the product label and nuclear-medicine protocol because they affect safety or image interpretation.
Supporting sources [1]
Relationship to Lu-177 dotatate
Both agents use receptor-targeted peptide delivery, but the isotope changes the purpose. Ga-68 primarily provides a PET signal; Lu-177 delivers therapeutic beta radiation. A diagnostic scan and a radionuclide treatment are separate procedures with different risk profiles.
Reading this profile
Jurisdiction: United States — FDA-approved prescription medicine; indication and formulation restrictions apply.. Molecular class: Gallium-68 radiolabeled somatostatin analog.
This profile was written with AI-assisted research and checked against the linked sources. It has not been represented as a clinician’s review. Evidence summaries describe the cited studies and products; they do not establish that a separately purchased preparation is equivalent.
Sources & references
Follow the original material. Product labels define specific formulations and uses; trial registration describes a study and does not by itself establish benefit.
- DailyMed: Netspot prescribing information ↗Regulatory source · Checked 2026-10-27
- Safety and Efficacy of 68Ga-DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine Tumors. ↗Original research · Checked 2026-10-27
- DailyMed: Lutathera prescribing information ↗Regulatory source · Checked 2026-10-27